| mRNA |
navitoclax:sorafenib (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.26 |
2e-13 |
| mRNA |
quizartinib |
CTRPv2 |
pan-cancer |
AAC |
0.25 |
2e-11 |
| mRNA |
tandutinib |
CTRPv2 |
pan-cancer |
AAC |
0.24 |
6e-11 |
| mRNA |
Sunitinib |
CTRPv2 |
pan-cancer |
AAC |
0.22 |
4e-10 |
| mRNA |
PF-573228 |
CTRPv2 |
pan-cancer |
AAC |
0.21 |
7e-10 |
| mRNA |
Ki8751 |
CTRPv2 |
pan-cancer |
AAC |
0.22 |
1e-09 |
| mRNA |
tretinoin:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.21 |
2e-09 |
| mRNA |
cabozantinib |
CTRPv2 |
pan-cancer |
AAC |
0.22 |
3e-09 |
| mRNA |
MGCD-265 |
CTRPv2 |
pan-cancer |
AAC |
0.2 |
1e-08 |
| mRNA |
BRD-K28456706 |
CTRPv2 |
pan-cancer |
AAC |
0.21 |
1e-08 |